Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center

Tenold, Matthew; Moskoff, Benjamin; Krishnan, Rajeev; Rosenberg, Aaron S; Hoeg, Rasmus T; Abedi, Mehrdad; Tuscano, Joseph M.; Jonas, Brian A.

doi:10.1016/j.clml.2021.02.007

Clinical Lymphoma Myeloma and Leukemia

2021

DOI: 10.1016/j.clml.2021.02.007

|View full text |Cite

Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center

Matthew Tenold

Benjamin Moskoff

Rajeev Krishnan

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Lymphoid markers as predictors of adult acute myeloid leukemia prognosis

Said,

Moussa,

Samra

et al. 2024

Egypt J Haematol

View full text Add to dashboard Cite

Background Acute myeloid leukaemia (AML) constitutes the most prevalent aggressive leukaemia in adults, with uncontrolled proliferation of immature myeloid cells and a variety of clinical manifestations. Whereas most AML patients respond to chemotherapy initially, half of all patients relapse within 5 years of being diagnosed. Aim and objectives The present study aimed to investigate the prognostic value of co expression of lymphocytes markers in patients with acute myeloid leukemia as regarding clinical outcome and survival. Patients and methods The present study was enrolled at Hematology Unit at Nasser Institute Hospital. This is a retrospective study done on (50) patients aged from 18 to 65 years, completion of treatment (or part of treatment undertaken), and follow-up duration of at least six months after diagnosis. Results The present study results showed a statistically significant difference between patients who achieved complete remission and those who relapsed or were refractory to treatment in the lymphoid markers CD7 and CD19. CD7 was the most frequent lymphoid marker. The lymphoid marker CD4 was associated with a higher complete remission rate. CD19 was associated with the highest relapse rate. Conclusion CD7 was the most frequent lymphoid marker. The lymphoid marker CD4 was associated with a higher complete remission rate compared to CD7, CD5, CD2 and CD19; While CD19 was associated with the highest relapse rate

show abstract

Lymphoid markers as predictors of adult acute myeloid leukemia prognosis

Said,

Moussa,

Samra

et al. 2024

Egypt J Haematol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center

Cited by 1 publication

References 17 publications

Lymphoid markers as predictors of adult acute myeloid leukemia prognosis

Lymphoid markers as predictors of adult acute myeloid leukemia prognosis

Contact Info

Product

Resources

About